Mineralys Therapeutics (MLYS) Analyst & Key Data

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

7

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$28.20

Median Target+68.44%

$47.50

Potential upside vs current price

DCF Value-91.03%

$2.53

Potential downside vs current price

Current Stock Price

$28.20

Median Target+68.44%

$47.50

Potential upside vs current price

DCF Value-91.03%

$2.53

Potential downside vs current price

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

7

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$28.20

Median Target+68.44%

$47.50

Potential upside vs current price

DCF Value-91.03%

$2.53

Potential downside vs current price

Current Stock Price

$28.20

Median Target+68.44%

$47.50

Potential upside vs current price

DCF Value-91.03%

$2.53

Potential downside vs current price

Mineralys Therapeutics, Inc.